Feltgen, Nicolas

[["dc.bibliographiccitation.firstpage","457"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","462"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Januschowski, Kai"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Spitzer, Bernhard"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Spital, Georg"],["dc.contributor.author","Dimopoulos, Spyridon"],["dc.contributor.author","Meyer, Carsten H."],["dc.contributor.author","Szurman, Gesine B."],["dc.date.accessioned","2018-11-07T10:26:58Z"],["dc.date.available","2018-11-07T10:26:58Z"],["dc.date.issued","2017"],["dc.description.abstract","Vision loss in central retinal vein occlusion (CRVO) is mostly caused by macular edema (ME) and can be treated with intravitreal bevacizumab injections. The goal of this study was to identify predictive factors for improvement in visual acuity. Three hundred and sixteen eyes of six centres having received intravitreal bevacizumab for ME due to CRVO were enrolled in this multicentre, retrospective, interventional case series. The follow-up time was 24 to 48 weeks. Investigated patient characteristics were pretreatment, duration of CRVO prior to the first injection, initial best-corrected visual acuity (BCVA), baseline central retinal thickness as measured by optical coherence tomography, gender, eye, age, comorbidity with glaucoma, systemic hypertension, or diabetes mellitus. Multiple regression analysis confirmed the following baseline predictive factors for an increase in visual acuity: low BCVA (p < 0.001), high CRT (p < 0.02), and treatment na < ve patients (p = 0.03). None of the other investigated patient characteristics could be identified as prognostic factors for increase in visual acuity (p > 0.1). Intravitreal injections of bevacizumab in a routine clinical setting effectively improved and stabilized BCVA in CRVO. Our large multicenter study identified initial BCVA, baseline CRT, and pre-treatment as prognostic factors for visual improvement."],["dc.identifier.doi","10.1007/s00417-016-3471-2"],["dc.identifier.isi","000394986600003"],["dc.identifier.pmid","27632214"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43151"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.title","Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","476"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","480"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Agostini, Hansjuergen T."],["dc.contributor.author","Bopp, S."],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2018-11-07T10:24:23Z"],["dc.date.available","2018-11-07T10:24:23Z"],["dc.date.issued","2017"],["dc.description.abstract","Macular bleeding is associated with an acute loss of visual function and is frequently a complication of neovascular age-related macular degeneration. Blood degradation products can lead to permanent retinal neuronal damage over time. The extent of the bleeding is correlated to the coagulation status of the patient. The treatment strategy depends on the age, size and exact location of the bleeding. The spectrum of therapeutic options ranges from watchful waiting to large scale vitrectomy with removal of subretinal mass bleeding."],["dc.identifier.doi","10.1007/s00347-017-0487-x"],["dc.identifier.isi","000400965300019"],["dc.identifier.pmid","28405758"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42653"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","829"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","830"],["dc.bibliographiccitation.volume","117"],["dc.contributor.author","Ziemssen, Focke"],["dc.contributor.author","Gelisken, F."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Priglinger, S."],["dc.date.accessioned","2021-04-14T08:26:11Z"],["dc.date.available","2021-04-14T08:26:11Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00347-020-01125-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81859"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","Viva Voce des EBO (European Board of Ophthalmology) Diploma: Prüfung unter Kollegen"],["dc.title.alternative","Tipps von der anderen Seite"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Die Ophthalmologie"],["dc.contributor.author","Plange, Niklas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bartz-Schmidt, Karl Ulrich"],["dc.contributor.author","Beyer, Tabea"],["dc.contributor.author","Hedergott, Andrea"],["dc.contributor.author","Holz, Frank"],["dc.contributor.author","Käsmann-Kellner, Barbara"],["dc.contributor.author","Lauermann, Jost Lennart"],["dc.contributor.author","Maier, Philip"],["dc.contributor.author","Stasik, Isabel"],["dc.contributor.authorgroup","Arbeitsgemeinschaft Lehre"],["dc.date.accessioned","2022-12-01T08:31:53Z"],["dc.date.available","2022-12-01T08:31:53Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung\n \n Hintergrund\n Der „Masterplan Medizin 2020“ umfasst eine 2017 verabschiedete politische Agenda von grundlegenden Veränderungen der medizinischen Ausbildung. Der Nationale Kompetenzbasierte Lernkatalog Medizin (NKLM) soll die inhaltliche Grundlage für diese Neustrukturierungen darstellen und wird in einer neuen Approbationsordnung rechtsverbindlich werden.\n \n \n Methode\n Der NKLM 2.0 wurde Ende 2021 verabschiedet. Die Grundlage ist ein kompetenzbasiertes Lernzielkonzept, welches die Arzt-Patienten-Kommunikation in das Zentrum des ärztlichen Handelns stellt. Die Struktur des NKLM soll dargestellt und die für die Lehre in der Augenheilkunde relevanten Inhalte sollen als Übersicht aufgearbeitet werden.\n \n \n Ergebnisse\n Spezifische Inhalte für die Lehre der Augenheilkunde finden sich in den Kapiteln V „Konsultationsanlässe“, Kapitel VI „Erkrankungen“, Kapitel VII „Übergeordnete und krankheitsbezogene Lernziele“ und Kapitel VIII „Übergeordnete Kompetenzen“. Die Kapitel werden stichpunktartig dargestellt.\n \n \n Schlussfolgerung\n Der NKLM 2.0 hat eine komplexe Struktur, die auf den ersten Blick nicht einfach zu durchdringen ist. Für die inhaltliche Neustrukturierung der Lehre der Augenheilkunde ist es notwendig, dass die Inhalte des NKLM 2.0 in der entsprechenden Tiefe vermittelt werden, da dieser in Zukunft rechtsverbindlich sein wird. Er bietet dennoch genug inhaltlichen Freiraum, um die Lerntiefe und die Lehre im Detail nicht einzuengen."],["dc.description.abstract","Abstract\n \n Background\n The Masterplan Medicine 2020 has been passed by German authorities in 2017 and will be the basis for future developments in teaching and medical education in Germany. The “Nationaler Kompetenzbasierter Lernzielkatalog” NKLM as a learning target index will be the substructure in terms of its content.\n \n \n Method\n The NKLM 2.0 has been finalized in 2021. The basic concept of skill-related learning will replace the pure teaching of medical facts. Physician-patient communication will be a central issue. The structure of the NKLM 2.0 is presented and the main topics for teaching in ophthalmology are discussed.\n \n \n Results\n The main chapters of the NKLM 2.0 that are directly related to topics in ophthalmology are chapter V medical conditions, chapter VI diseases, chapter VII comprehensive learning targets and chapter VIII comprehensive competences.\n \n \n Conclusion\n New teaching standards in ophthalmology need to include the topics and learning targets of the NKLM 2.0, as the NKLM will be legally binding in the future. It should be the basis but not exclusively, to improve educational standards in ophthalmology."],["dc.identifier.doi","10.1007/s00347-022-01753-w"],["dc.identifier.pii","1753"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118298"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2731-7218"],["dc.relation.issn","2731-720X"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Der Nationale Kompetenzbasierte Lernzielkatalog Medizin NKLM 2.0 – Auswirkungen auf die Lehre in der Augenheilkunde"],["dc.title.translated","The “Nationaler Kompetenzbasierter Lernzielkatalog Medizin NKLM 2.0”—Implications for medical education in ophthalmology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1066"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","1069"],["dc.bibliographiccitation.volume","115"],["dc.contributor.author","Lauermann, P."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Khattab, M."],["dc.contributor.author","Storch, M."],["dc.contributor.author","Hoerauf, H."],["dc.date.accessioned","2020-12-10T14:10:16Z"],["dc.date.available","2020-12-10T14:10:16Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00347-018-0652-x"],["dc.identifier.eissn","1433-0423"],["dc.identifier.issn","0941-293X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70701"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Zunehmende Lipidexsudation und Gefäßveränderungen assoziiert mit einem Aderhautnävus"],["dc.title.alternative","Increasing lipid exudation and vascular alterations associated with a choroidal nevus"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1157"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Klinische Monatsblätter für Augenheilkunde"],["dc.bibliographiccitation.lastpage","1161"],["dc.bibliographiccitation.volume","230"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Holz, Frank G."],["dc.contributor.author","Kramer, Anneke"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Krohne, T."],["dc.contributor.author","Behrens-Baumann, W."],["dc.date.accessioned","2018-11-07T09:17:51Z"],["dc.date.available","2018-11-07T09:17:51Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1055/s-0033-1351015"],["dc.identifier.isi","000328101800020"],["dc.identifier.pmid","24243478"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28267"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1439-3999"],["dc.relation.issn","0023-2165"],["dc.title","Statement of the German Ophthalmological Society, the Retinolgical Society and the Professional Association of Eye Specialists Germany: Endophthalmitis-Prophylaxeis in intravitreal operative Drug Administration (Effective July 2013)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","919"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","924"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T14:10:18Z"],["dc.date.available","2020-12-10T14:10:18Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00347-019-0935-x"],["dc.identifier.eissn","1433-0423"],["dc.identifier.issn","0941-293X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70715"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Aktueller Stellenwert von schweren Flüssigkeiten als intraoperative Hilfsmittel bei vitreoretinalen Eingriffen"],["dc.title.alternative","Current importance of heavy fluids as intraoperative aids in vitreoretinal surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","479"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","492"],["dc.bibliographiccitation.volume","107"],["dc.contributor.author","Baraki, H."],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Roider, J."],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Klatt, C."],["dc.date.accessioned","2018-11-07T08:43:46Z"],["dc.date.available","2018-11-07T08:43:46Z"],["dc.date.issued","2010"],["dc.description.abstract","In the acute stage central serous chorioretinopathy (CSC) is characterized by serous retinal detachment. Monofocal or multifocal structural changes of the pigment epithelium layer are common. Unilateral blurred vision is the major clinical symptom. The pathogenesis is unclear but corticosteroids and stress may trigger the disease. Normal vision often returns spontaneously within a few months. Therapeutic options are at a low evidence level. Carbonic anhydrase, mild laser photocoagulation, selective retinal therapy, photodynamic therapy and the intravitreal injection of bevacizumab have been reported. The authors suggest a treatment strategy on the basis of the available data."],["dc.identifier.doi","10.1007/s00347-010-2154-3"],["dc.identifier.isi","000277596000014"],["dc.identifier.pmid","20454897"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20051"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0941-293X"],["dc.title","Central serous chorioretinopathy (CSC)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","499"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","504"],["dc.bibliographiccitation.volume","115"],["dc.contributor.author","Storch, M."],["dc.contributor.author","Bemme, S."],["dc.contributor.author","Rehak, M."],["dc.contributor.author","Hoerauf, H."],["dc.contributor.author","Feltgen, N."],["dc.date.accessioned","2020-12-10T14:10:15Z"],["dc.date.available","2020-12-10T14:10:15Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00347-017-0513-z"],["dc.identifier.eissn","1433-0423"],["dc.identifier.issn","0941-293X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70696"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Ultraweitwinkelangiographie beim retinalen Venenverschluss"],["dc.title.alternative","Ultra-widefield angiography for retinal vein occlusion. How large is large enough?"],["dc.title.subtitle","Wie groß ist groß genug?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","681"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Klinische Monatsblätter für Augenheilkunde"],["dc.bibliographiccitation.lastpage","693"],["dc.bibliographiccitation.volume","227"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Pielen, A."],["dc.contributor.author","Hansen, L."],["dc.contributor.author","Bertram, B."],["dc.contributor.author","Agostini, Hansjuergen T."],["dc.contributor.author","Jaissle, Gesine B."],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Stahl, Andreas"],["dc.date.accessioned","2018-11-07T08:39:57Z"],["dc.date.available","2018-11-07T08:39:57Z"],["dc.date.issued","2010"],["dc.description.abstract","The novel therapeutic principle of intravitreal drug therapy for retinal vein occlusion has become an integrated constituent of clinical practice over the last years. The two substance classes that have been evaluated in large randomised clinical trials so far are corticosteroids and inhibitors of vascular endothelial growth factor (VEGF). The reported treatment success of these intravitreally administered substances has lead not only to a paradigm shift in clinical care but has also advanced our understanding of the underlying pathophysiological principles of retinal vein occlusions. In this review the different substances are discussed, their mechanisms of action are analysed and the results of the large clinical trials available to date are critically evaluated. Furthermore, an approach to integrate these novel treatment options into the exisitng treatment regimes for retinal vein occlusions is suggested."],["dc.identifier.doi","10.1055/s-0029-1245606"],["dc.identifier.isi","000281860800003"],["dc.identifier.pmid","20845248"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19117"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1439-3999"],["dc.relation.issn","0023-2165"],["dc.title","Intravitreal Drug Therapy for Retinal Vein Occlusion - Pathophysiological Mechanisms and Routinely Used Drugs"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]